Table 1.

Patient Characteristics stratified by patients Progressing on their current treatment verses patients responding

	Progression (n=7)	Responding (n=19)
Age, median (range), yrs	65 (55–78)	68 (60–83)
Time since diagnosis (range), yrs	7 (1–10)	9(1–17)
PSA at blood draw, median (range), ng/mL	276 (45.2–780)	13.3 (0.07– 369.1)
Gleason Score, #, (%)
≤7	3 (43)	7 (37)
≥8	3 (43)	10 (53)
Poorly differentiated	1 (14)	2 (10)
Presence of Bone Metastasis,#, (%)
Yes	7 (100)	18 (95)
No	0 (0)	1 (5)
Presence of Visceral Metastasis,#, (%)
Yes	2 (29)	3 (16)
No	5 (71)	16 (84)
Current/Prior use of Enzalutamide / ARN-509,#, (%)
Yes	5 (71)	3 (16)
No	2(29)	16 (84)
Current /Prior use of Abiraterone Acetate / VT-464 / TAK700, #, (%)
Yes	5 (71)	10 (53)
No	2(29)	9 (47)
Current /Prior use of Docetaxel,#, (%)
Yes	4 (57)	9 (47)
No	3 (43)	10 (53)